대한뉴팜

Daehan Nupharm’s health supplement brand DiNU: will host a special Naver Shopping LIVE broadcast in collaboration with Fitvely, a fitness influencer with over 1.46 million YouTube subscribers. The event will offer exclusive discounts on DiNU’s flagship products and include special giveaways. During the live show, Paraotics (probiotics), DiNU Ascorbic Acid (Vitamin C), and DiNU MSM will be available at special promotional prices. Viewers will also have the chance to win prizes through on-air giveaways and lucky draws. The broadcast will air live on September 15, 2025, at 8:00 PM via Naver Shopping LIVE. [Live Broadcast Page] https://view.shoppinglive.naver.com/lives/1731478[Event Preview Page] https://shoppinglive.naver.com/livebridge/1731478

Daehan Nupharm has completed the construction of its new GMP-certified production plant with a total floor area of 15,150 square meters, marking a significant step forward in the company’s journey to become a global pharmaceutical and biotech leader.The new facility was completed through a 14month process that began with conceptual design in February 2023, followed by a groundbreaking ceremony in May and the start of construction in June of the same year. More than 35,000 workers participated in the project, with a total investment of approximately KRW 81 billion. The state-of-the-art plant is equipped with an injectable production line that fully complies with the EU GMP Annex 1 guidelines, as well as a solid dosage production line incorporating a BIN system to minimize exposure. Once fully operational, the facility will have the capacity to produce 800 million tablets and 200 million capsules annually. Validation and product transfer processes are currently underway, with full-scale operations scheduled to begin in January 2027. This new plant represents the second phase of the “Hyangnam Project 1·2·3”, which began in 2022. Phase 1, the R&D center, was completed in June 2023, and Phase 3 will involve the construction of an automated warehouse. The Phase 2 GMP facility is regarded as a pivotal milestone in this long-term strategic initiative. The completion of the new facility is the result of years of preparation and investment. Daehan Nupharm plans to complete product transfer seamlessly and begin producing new R&D pipeline products at the plant. Beyond simply expanding production capacity, this facility will serve as a solid foundation for the stable supply of high-quality pharmaceuticals and expansion into global markets. Looking ahead, Daehan Nupharm will continue to strengthen its R&D capabilities and accelerate its growth as a global pharmaceutical and biotech company.

Daehan Nupharm recorded KRW 101.7 billion in sales and KRW 7.3 billion in operating profit in the first half of 2025. The company has maintained profitability for 18 consecutive quarters since 2021. Although sales and operating profit decreased by 0.7% and 32.4% year-on-year.Respectively, this reflects the company’s strategic investments and transitional adjustments to secure a stronger growth foundation for the future. The results were primarily impacted by increased R&D expenditures and CSO-related fees. R&D investment totaled KRW 6.8 billion, accounting for 6.7% of total sales — a 3% increase year-on-year. This increase reflects the company’s ongoing efforts to strengthen its R&D pipeline and expand research personnel and equipment ahead of its new plant operations. Currently, the Central Research Institute is developing 10 improved drug candidates, while the Biotech Research Institute is conducting research on four new drug candidates. Among them, a veterinary biopharmaceutical product is expected to complete clinical trials this year and launch next year, making it the first to be commercialized. Rather than focusing on short-term profitability, Daehan Nupharm is prioritizing strategic investments to strengthen technological competitiveness and expand its product portfolio. The company is channeling its R&D capabilities to align with the upcoming GMP plant operations and plans to drive growth and increase corporate value through new product launches and global market expansion. Moving forward, Daehan Nupharm will continue to enhance its competitiveness in the pharmaceutical industry by investing in R&D and upgrading production infrastructure, securing a solid momentum for sustainable growth.

Daehan Nupharm held the “The Force of Non-Reimbursement” Symposium from July 19 to 20 at JW Marriott Dongdaemun Square Seoul. The two-day symposium focused on oral medications for obesity management and injectable therapies in functional medicine, bringing together experts and healthcare professionals to share clinical insights and real-world prescribing experiences.A total of four medical experts participated as speakers, and more than 70 healthcare professionals attended the event. The program featured product presentations, case studies, and clinical discussions on non-reimbursable treatment options. On the first day, the sessions included: ▶“Obesity Solution Through Real-World Data (Oral & IVNT)” by Dr. Donghun Yang (ROEM Clinic) ▶“Practical Protocols for IVC in Oncology: Where Do You Mix IVC?” by Dr. Sangjun Kwak (Amina Hospital) On the second day, lectures were delivered on: ▶“Carbohydrate Absorption Blockers for Obesity and a Dual-Licensed Physician’s View on Bangpoongtongseongsan” by Dr. Sunhyung Kim (G7 Clinic) ▶“K-IVNT: Getting Started with IV Therapy” by Dr. Jaehwan Lee (Hyosarang Family Medicine Clinic) During the opening remarks, CEO Wonsuk Lee emphasized two key strategic initiatives: “First, we are building a new plant at our Hyangnam site to expand and enhance our production facilities, ensuring the highest quality pharmaceutical products,” he stated. “Second, we will continue to strengthen our R&D capabilities to offer a more diverse range of treatment options.” The symposium provided an opportunity for medical professionals to explore practical approaches to non-reimbursable therapies, reflecting Daehan Nupharm’s ongoing commitment to supporting evidence-based clinical practice and advancing treatment options in the healthcare field.

Daehan Nupharm announced on the 26th that it is participating in “Cosmoprof CBE Asean Bangkok 2025”, which is currently being held in Bangkok, Thailand. The exhibition, hosted in Thailand’s rapidly growing beauty and medical aesthetics market (estimated at USD 6.6 billion), has been drawing increasing global attention since moving its venue to central Bangkok in 2023. At this year’s event, Daehan Nupharm is showcasing a diverse portfolio, including Luthione Injection, anesthetic creams, PLA fillers, facial mask packs, and diagnostic kits. Thailand has shown strong and growing demand for K-beauty and Korean-made medical products, with imports rising significantly over the past three years. Korea currently holds the No. 1 market share in cosmetics imported into Thailand and ranks 10th in medical device imports, reflecting the country’s robust growth driven by active market expansion efforts from Korean companies. Daehan Nupharm has been actively expanding its global presence, having completed overseas registration for 75 products to date, with 11 additional products registered in 2024 alone. The company has established a broad export network spanning Southeast Asia, Central Asia, the Middle East, South America, and New Zealand. Pharmaceutical product registration requires CTD (Common Technical Document) submissions, which include extensive data on raw materials, manufacturing processes, and toxicology studies. Because this process — including site inspections — can take several years depending on the country, a strategic approach backed by specialized expertise is essential. Daehan Nupharm is pursuing a long-term export growth strategy ahead of the full operation of its new Hyangnam GMP facility in 2027. Participating in global exhibitions is a key part of this plan. While the company’s appearance at last year’s Cosmoprof Hong Kong focused on identifying demand for its new products such as PLA fillers and anesthetic creams, this year’s Bangkok exhibition aims to promote finished products, conduct sample testing with potential buyers, and generate export revenue starting in the second half of 2025.

Amid a severe nationwide influenza outbreak in Korea, Daehan Nupharm has reported a sharp increase in demand for its “Enpiflu Premix Injection,” a one-shot IV treatment for influenza. The number of flu patients visiting medical facilities has skyrocketed to more than ten times the usual levels, with some pharmacies already experiencing shortages of flu treatments and cold medicines. According to the Korea Disease Control and Prevention Agency (KDCA), the number of suspected influenza outpatients during the last week of December 2024 (December 22) reached 73.9 per 1,000, up from 7.3 per 1,000 in early December—a tenfold increase and the highest figure since the major flu outbreak in 2016. Influenza typically presents with sudden high fever (over 38 °C), headache, muscle pain, fatigue, and respiratory symptoms such as cough, sore throat, and sputum production. If left untreated in the early stages, it can lead to complications including pneumonia, bronchitis, and worsening of chronic conditions. Enpiflu Premix Injection is a peramivir hydrate-based formulation that treats influenza with a single intravenous dose, unlike Tamiflu(oseltamivir), which requires two oral doses per day for five days. It is approved by the Ministry of Food and Drug Safety for the treatment of influenza A and B infections in adults and children aged two years and older.Notably, single-dose peramivir therapy demonstrated comparable symptom improvement to Tamiflu in a clinical study involving 1,091 adult patients across 146 medical institutions in Korea, Japan, and Taiwan who received treatment within 48 hours of symptom onset.Building on the success of its IV treatment portfolio, Daehan Nupharm is set to expand its product lineup with the launch of Arginine Premix Injection in March 2025. Arginine, a semi-essential amino acid and pro-drug of nitric oxide (NO), is often supplemented externally due to its limited natural production in the body. It is widely known to support metabolic health, vitality, and sexual function. Unlike conventional vial formulations that dominate the domestic arginine injection market, Daehan Nupharm’s Arginine Premix Injection comes in a ready-to-use IV bag, eliminating the need for compounding, preventing potential contamination during mixing, and enabling safer and more convenient administration.

Daehan Nupharm recorded cumulative sales of KRW 151.2 billion and operating profit of KRW 14.9 billion for the third quarter of 2024.Net profit for the same period reached KRW 12.8 billion. For the third quarter alone, the company posted sales of KRW 48.8 billion and operating profit of KRW 4.0 billion, continuing its strong financial performance. This growth was largely driven by solid sales in its core pharmaceutical business and the successful launch of its new gastroesophageal reflux disease (GERD) treatment,"Rapiduo".Rapiduo is the first and only combination therapy in Korea that pairs rabeprazole with magnesium oxide in a dual-core PPI formulation designed to improve quality of life for GERD patients. The outer layer of magnesium oxide rapidly neutralizes gastric acid and increases pH levels, protecting the inner core of rabeprazole from acid degradation and enabling effective release in the stomach. The product reaches peak plasma concentration within one hour and features reduced tablet size through dual-core technology, enhancing patient convenience. To accelerate market penetration and strengthen product awareness, Daehan Nupharm has been actively organizing medical symposiums. The “Double Protection DUO” symposium series, held three times this month, focuses on Lapiduo’s clinical value. On October 20, a session will feature Professor Ji-Won Kim (Boramae Medical Center) as chair, with lectures by Professor Jung-Won Jeon (Kyung Hee University Hospital at Gangdong) and Dr. Joong-Won Yoon (Samsung Top Internal Medicine Clinic) covering topics such as “Pharmacotherapy for Peptic Ulcers” and “Best Practices for PPI Prescribing in Primary Care.” In addition, the company continues to host its “Obesity & Wellness Injection Symposium” series, launched last year to share medical knowledge in the weight management and wellness field. Starting in Busan, followed by Seoul and Gyeongju, these events serve as key platforms to highlight Daehan Nupharm’s expertise and expand its presence in the market.

Daehan Nupharm recorded KRW 102.4 billion in sales, KRW 10.8 billion in operating profit, and KRW 10.8 billion in net profit for the second quarter of 2024, continuing its solid profitability trend. The strong performance was largely driven by stable growth in the company’s core pharmaceutical business, particularly the successful launch of its gastroesophageal reflux disease (GERD) treatment, Rapiduo Tab. Actively promoted since its release, Rapiduo Tab. combines rabeprazole (PPI) with magnesium oxide, achieving peak plasma concentration within one hour, significantly faster than existing PPI formulations (6~7 hours), thereby overcoming a key limitation of conventional products.In parallel with its commercial success, Daehan Nupharm is expanding its R&D pipeline through specialized research organizations, including the Central Research Institute for human pharmaceuticals, the Biotech Research Institute for biopharmaceuticals, and the Animal Health Research Institute for veterinary medicines.The Central Research Institute plans to add a high-dose 20/350 mg formulation of Rapiduo Tab., while also conducting active research on improved combination drugs for hypertension, hyperlipidemia, and obesity. The Biotech Research Institute is working with domestic biotech companies and overseas research institutes to develop antiviral therapies. Meanwhile, the Animal Health Research Institute has achieved notable milestones, including the 2023 launch of Teramin Tab. (terbinafine) and the world’s first fluconazole formulation for companion dogs, DH Fuzole Tab., launched in June 2024, following earlier development of the human formulation, Fuzole Tab. Beyond R&D investment, Daehan Nupharm is constructing a new GMP production facility to enhance its manufacturing capacity. The new plant will be equipped with state-of-the-art production systems to ensure the large-scale supply of high-quality pharmaceuticals.

Daehan Nupharm has announced the launch of two new veterinary medicines under its exclusive animal hospital brand, DiAange‘DH Fuzole Tab.’, the world’s first fluconazole formulation developed specifically for dogs ‘PROCOX Tab.’, an NSAID (non-steroidal anti-inflammatory drug) containing firocoxib. DH Fuzole Tab. is an antifungal treatment for Malassezia dermatitis, one of the most common dermatological conditions in companion dogs. Skin disorders account for a significant portion of veterinary consultations, and antifungal agents make up a large share of prescribed medications in this field. While human antifungal drugs such as itraconazole, fluconazole, and terbinafine are widely used, there has been a lack of verified animal-specific antifungal formulations, leading veterinarians to rely on human medicines. To address this unmet need, Daehan Nupharm has been actively developing veterinary antifungal products to provide veterinarians with more tailored treatment options. Following the 2023 launch of Teramin Tab. (terbinafine) and several years of development since 2019 based on the human formulation Fuzole Tab., the company has now achieved a global milestone, securing regulatory approval for the world’s first fluconazole formulation for dogs. The newly introduced PROCOX Tab., formulated with firocoxib, offers fast and potent pain relief with high COX-2ivity and minimal COX-1 inhibition. Thisive action reduces the risk of gastrointestinal side effects commonly associated with non-selective NSAIDs. As companion dogs live longer and chronic conditions become more prevalent, the market for veterinary NSAIDs (e.g., meloxicam, carprofen, firocoxib) continues to expand annually. Currently, the domestic market relies heavily on imported products from global pharmaceutical companies. The launch of PROCOX Tab. is expected to enhance treatment accessibility and cost efficiency through local manufacturing while broadening therapeutic options for veterinarians. Daehan Nupharm is committed to transitioning human drugs into veterinary formulations to ensure safer and more effective treatments for animals. The company plans to obtain regulatory approval for three additional veterinary products and file an IND (Investigational New Drug) application for one new compound within this year.